CORRECTION: Verona Pharma Q2 EPADS $(0.11) Beats $(0.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Verona Pharma (NASDAQ:VRNA) reported Q2 losses of $(0.11) per ADS, beating the analyst consensus estimate of $(0.27) by 59.26%. This represents a 65.63% increase over losses from the same period last year.
August 04, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma reported better than expected Q2 losses, which could positively impact the stock in the short term.
Verona Pharma's Q2 losses were significantly less than analyst estimates, which is generally seen as a positive sign by investors. This could lead to increased demand for the stock, potentially driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100